COMPANY RESEARCHPAQ develops KRAS degraders. The registered Phase 1 PT0253 study is in advanced solid tumors with KRAS G12D mutations. Historical autophagy positioning was not substituted for current technical disclosures.
$77 million is the total Series B, including the original $39 million. It is neither incremental extension proceeds nor lifetime cumulative company financing.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
NCT06797336 registers a PAQ-sponsored Phase 1 PT0253 monotherapy study, with an actual start date of 2024-12-19. The website identifies a KRAS degradation approach.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| PT0253 | KRAS G12D · Advanced solid tumors with KRAS G12D mutations | Phase 1 | Clinical registration exists; public results not confirmed in this review |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
PAQ Therapeutics plans to present the first clinical findings for selective KRAS G12D degrader PT0253 at ENA 2026 in Barcelona on November 20. The oral presentation will draw on an ongoing Phase 1 study in advanced solid tumors; a separate poster covers preclinical work. The announcement did not disclose quantitative efficacy results.
Amphista announced an ASH oral presentation on AMX-883-mediated BRD9 degradation, describing disruption of hematopoietic transcriptional programs, myeloid differentiation, and reduced leukemic stem-cell frequency in experimental work. A separate abstract outlines the ongoing Phase 1 BRAMLIE study in AML and high-risk myelodysplastic syndrome. The announcement does not establish clinical efficacy for AMX-883.
Nurix announced updated Phase 1a/1b findings for its oral BTK degrader bexobrutideg (NX-5948) in relapsed or refractory CLL/SLL. The ASH presentation will include patients previously exposed to covalent BTK inhibitors and data at the recommended Phase 2 dose of 600 mg once daily. The release describes durable activity without providing numerical response rates.
A PNAS study reports RHV, a tetravalent bispecific protein designed to internalize and lysosomally degrade VCAM-1 and VEGFR on pathological vessels. The original abstract describes activity in mouse choroidal neovascularization models, including efficacy comparable to aflibercept at one-quarter of the molar dose. This is preclinical extracellular receptor degradation, distinct from an intracellular small-molecule PROTAC.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.
